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EDITORIAL
Are Anaplastic Lymphoma Kinase Gene Rearrangements in
Non-small Cell Lung Cancer Prognostic, Predictive,
or Both?
Benjamin Solomon, MBBS, PhD,* and Alice T. Shaw, MD, PhD†
Many aspects of the clinical and pathological phenotype of non-small cell lung cancer(NSCLC) harboring rearrangements in the anaplastic lymphoma kinase (ALK) gene
have been characterized following the description of the EML4-ALK fusion gene in
NSCLC in 2007.1,2 These tumors most frequently occur in younger, never or light smokers
with adenocarcinoma, are almost always mutually exclusive with EGFR or KRAS
mutations, and demonstrate exquisite sensitivity to treatment with the ALK inhibitor
crizotinib.3 However, there are few published data regarding the natural history and
clinical outcomes of ALK-positive NSCLC. Two reports in this issue of the Journal of
Thoracic Oncology, conducted in different patient populations using different methods to
detect ALK rearrangements, provide apparently conflicting conclusions about the prog-
nostic significance of ALK gene rearrangements in NSCLC and raise questions about the
optimal method to detect ALK gene rearrangements in clinical samples.
In the first study, Wu et al. performed a retrospective analysis using reverse
transcription polymerase chain reaction (RT-PCR) to detect ALK gene rearrangements in
cell pellets derived from malignant pleural effusions in 116 EGFR wild-type, Taiwanese
patients with stage IIIB/IV NSCLC. Thirty-nine patients (34%) were found to have ALK
gene rearrangements and, in contrast to other studies, these patients did not differ from
ALK-negative patients with respect to age or smoking history. Wu et al. observed better
median survival in the ALK-positive patients compared with the EGFR wild-type,
ALK-negative patients (14.7 versus 10.3 months, p  0.009). In the second study, Yang
et al. screened 300 never smokers from the Mayo Clinic Lung Cancer Cohort with a
two-staged process involving immunohistochemistry (IHC) using the commercially avail-
able monoclonal ALK1 antibody (Dako, Capinteria, Ca) followed by fluorescence in situ
hybridization (FISH) using break-apart probes (Vysis, Des Plaines, IL). In this cohort of
predominantly early-stage tumors (191/300 stage I/II, 62/300 stage II, and 47/300 stage
IV), 22 patients (8.2%) were determined to be ALK-positive by FISH. No overall survival
data are presented, but using a composite end point of 5-year progression-free survival
(PFS) and recurrence-free survival, adjusted for stage and treatment modality, Yang et al.
found inferior outcomes in the ALK-positive cohort, with a twofold increase in the risk of
experiencing disease progression or recurrence within 5 years in ALK-positive compared
with ALK-negative patients.
How do these articles with apparently contradictory findings fit in with what is
known about clinical outcomes in this patient population? Of note, assessment of the
predictive and prognostic significance of ALK gene rearrangements in NSCLC is limited
by the fact that, with the exception of one prospective, single-arm study,3 the published
data are limited to relatively small retrospective studies. Furthermore, the possibility of
ascertainment bias cannot be excluded because of potential differences in the populations
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screened for ALK rearrangements in these studies compared
with the broader population of NSCLC patients.
With these caveats in mind, retrospective data have
been reported regarding outcomes in ALK-positive patients
treated with platinum doublets, pemetrexed, or EGFR ty-
rosine kinase inhibitors (TKIs). Three retrospective studies
have indicated that ALK rearrangements do not seem to
predict additional benefit from platinum-based combination
chemotherapy compared with other genotypes. Shaw et al.4
first reported that the response rate and time to progression in
patients with ALK-rearranged tumors treated with platinum
doublets were not different compared with patients whose
tumors had EGFR mutations or were wild-type for both ALK
and EGFR. This finding has since been replicated in two
independent series reported from South Korea.5,6 Intrigu-
ingly, two retrospective studies have reported improved re-
sponse rates7 and PFS7,8 after treatment with pemetrexed in
ALK-positive patients compared with patients with tumors of
other genotypes. Perhaps not surprisingly, ALK rearrange-
ments seem to be negative predictors for benefit from EGFR
TKIs. Across three retrospective studies, no patients with
ALK gene rearrangements responded to EGFR TKIs.4–6 Fur-
thermore, PFS after erlotinib or gefitinib was inferior in
ALK-positive tumors compared with other genotypes.4–6
Due to crossover in the ongoing randomized phase III
trials of crizotinib, and the recent accelerated approval of
crizotinib by the U.S. Food and Drug Administration (FDA),
the effects of ALK inhibitors on survival are unlikely to be
prospectively established. However, data from crizotinib-
treated and crizotinib-naive ALK-positive cohorts point to
ALK gene rearrangements being (1) predictive of response to
ALK inhibitors3 and (2) associated with survival benefit from
these agents.9
In NSCLC patient populations where ALK has been
genotyped, there does not appear to be a positive prognostic
effect of ALK rearrangements on survival in the absence of
treatment with crizotinib. In a recent report of a cohort from
United States and Australia, the median overall survival in 36
crizotinib-naive, ALK-positive controls was similar to that in
253 wild-type controls (20 versus 15 months, p  0.244).9 In
an independent cohort of 229 Korean nonsmokers with
NSCLC,5 median overall survival in ALK-positive patients
(14.3 months) was similar to patients with KRAS mutations
(15.6 months) and inferior to patients with EGFR mutation
(37.4 months) or “triple-negative” patients (33.3 months).
Kim et al. also analyzed recurrence-free survival in 119
patients who were managed with surgery. Recurrence-free
survival was 39.7 months for EGFR mutations, 20 months for
ALK rearrangements, 21.4 months for KRAS mutations, and
26.8 months for the triple-negative patients. These findings
are consistent with those reported by Yang et al. who showed
a twofold increase in the risk of experiencing lung progres-
sion or recurrence within 5 years. Taken together, these data
suggest that ALK-positive patients do not have improved
outcomes compared with other genotypes and potentially
provide an argument for clinical trials of ALK inhibitors in
the adjuvant setting.
The natural history of ALK-rearranged NSCLC does,
however, seem to be modified by treatment with crizotinib
with improved survival in crizotinib-treated patients com-
pared with ALK-positive patients never exposed to crizo-
tinib.9 Survival in 30 ALK-positive patients who were given
crizotinib in the second- or third-line setting was significantly
longer than in 23 ALK-positive, crizotinib-naive controls
given any second-line therapy (hazard ratio 0.36, 95% con-
fidence interval 0.17–0.75; p  0.004). In fact, survival in 56
crizotinib-treated, ALK-positive patients was similar to that
in 63 ALK-negative, EGFR-positive patients given EGFR
TKI therapy. These data appear to be supported by a recent
study by Paik et al. of patients genotyped for EGFR, KRAS,
and ALK in the “postcrizotinib era”: patients with ALK
rearrangements had outcomes that were similar to patients
with EGFR mutations and improved compared with those
with KRAS mutations.10
These two articles raise important questions about the
optimal strategy to detect patients with ALK gene rearrange-
ments, the subject of a recent editorial in this journal.11 The
technique used by Wu et al. to identify ALK-positive patients
was RT-PCR from frozen cell pellets derived from pleural
effusions. This assay requires extraction of RNA from clin-
ical samples, is not routinely performed in many diagnostic
pathology laboratories, and suffers from some important
limitations. Each PCR assay is ALK fusion-specific, and
although assays may be multiplexed,12 they may not detect all
possible ALK gene rearrangements, especially those involv-
ing novel fusion partners,13 a consequence of which may be
false-negative results. Another important limitation is the
possibility of contamination which might impair specificity and
lead to false-positive results.14 Discordant data in the small
subset of patients who underwent both FISH and RT-PCR
testing raises the possibility of both false positives and false
negatives, a finding that could account for the discrepant find-
ings regarding survival in the report by Wu et al.
Yang et al. expand on previous experience15 evaluating
the approach of initial testing using IHC with the commer-
cially available monoclonal ALK1 antibody and an enhanced
detection system paired with subsequent FISH testing. They
observed complete concordance between samples scored as
IHC 3 and FISH positivity and also between samples
scored as IHC 0 and FISH negativity. However, in the case of
IHC 2, 14.3% of cases were FISH positive and in the case
of IHC 1 only 3.1% of cases were FISH positive, indicating
that IHC was sensitive but not specific. On this basis, upfront
testing of all patients with IHC coupled with confirmatory
testing by FISH in IHC 2 (and selected IHC 1) cases is
suggested. Similar strategies have been proposed using an-
other commercially available antibody (Clone 5A4, Novocas-
tra, Newcastle, United Kingdom)16 and a novel antibody that
is yet to be made commercially available (D5F3, Cell Sig-
naling, Danvers, MA).13
The proposed algorithm, analogous to that recommended
for the detection of HER2 amplification in breast cancer,17 is
attractive and has advantages with respect to improving the
accessibility and cost-effectiveness of screening for ALK rear-
rangements in NSCLC. However, large-scale multicenter pro-
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spective validation of this approach is essential. A cautionary
note is provided by experience with HER2 testing in breast
cancer where there has been at least a 20% discordance reported
between community-based HER2 assays and central laboratory
testing.18,19 This has led to recommendations to reduce preana-
lytic, analytic, and postanalytic variation including sample han-
dling (e.g., tissue processing and method of fixation), standard-
ization of reagents and protocols, standardized reporting criteria,
and implementation of quality assurance procedures (including
the requirement for laboratory accreditation and external profi-
ciency assessments).17 Nonetheless, even in this arena, where
the FDA has approved several IHC, FISH, and chromogenic in
situ hybridization (CISH) assays for detection of HER2 ampli-
fication, controversy remains about whether the best diagnostic
approach is a combination of IHC and FISH17 or whether all
tumors should have primary testing with FISH or CISH.20
NSCLC with ALK gene rearrangements represent a
distinct entity with clinical and pathological features that are
characteristic but overlap with other subsets of NSCLC.
Molecular characterization of ALK status is essential as it
identifies patients suitable for treatment with crizotinib, an
agent that likely impacts the natural history of ALK-positive
NSCLC. Development and validation of strategies to improve
effective identification of this patient population with strate-
gies incorporating IHC or other techniques are important and
likely to assume a place in clinical practice. However, for
now, FISH with break-apart probes remains the gold standard
and is the only FDA-approved test for identification of
NSCLC patients with ALK gene rearrangements who may be
eligible for treatment with crizotinib.
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